Corgenix Expands Scientific Advi...( DENVER June 17 /- Corgenix Medica...)

DENVER, June 17 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, announced today the appointment of Barry L. Molk, M.D., F.A.C.C., and Charles H. Miranda, M.D., F.A.C.P., F.A.A.P., to its scientific advisory board.

Drs. Molk and Miranda join Luis Lopez, M.D., Corgenix Chairman and Chief Medical Officer, expanding the number of scientific advisory board members to three.

"These two individuals bring a wealth of knowledge and expertise to our organization," said Douglass Simpson, Corgenix' President and Chief Executive Officer. "Their appointment strengthens the clinical and scientific guidance required for the successful development, manufacturing and marketing of our diagnostic testing products."

Dr. Molk has been affiliated with Aurora Denver Cardiology Associates since 1976 and has served as Chief of Cardiology at Sky Ridge Medical Center since 2003. He is board certified in internal medicine and cardiovascular diseases and is also a Fellow of the American College of Cardiology (F.A.C.C.).

After receiving his medical degree from the University of Colorado Health Sciences Center (UCHSC), Dr. Molk completed his residency training at Baylor Affiliated Hospitals and UCHSC, and is fellowship trained in cardiology from UCHSC. He maintains a teaching appointment as Associate Clinical Professor of Medicine, UCHSC.

Dr. Miranda is currently in private practice in internal medicine and pediatrics at South Denver Internal Medicine and Pediatrics, P.C. in Denver. Previously, he practiced internal medicine and pediatrics for 10 years at the world-renowned Texas Medical Center in Houston. Miranda is board certified by the American Board of Internal Medicine and the American Board of Pediatrics. He is a Fellow of the American Academy of Pediatrics (F.A.A.P.) and the American College of Physicians (F.A.C.P.).

Dr. Miranda received his medica
'/>"/>